| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84b0ac731eeb01f0905b411485bfd591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate |
2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a0254a8c2bd35ef8a71df662efcd29c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c818a75d60b16671925b7ff48e3df0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9cc6676b33d420f7443fd1bd5b253be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05e98b99116194c15daefdc63c976ba3 |
| publicationDate |
2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019072885-A1 |
| titleOfInvention |
MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER |
| abstract |
The present invention relates to methods and pharmaceutical compositions for the treatment of cancer in a subject in need of such treatment. Therapeutic strategies using drugs that cause death of lysosomal cells have been proposed for the eradication of resistant cancer cells. Magnetic nanoparticle (MNP) -based nano-therapy based on magnetic lysosomal hyperthermia (MILH) that is grafted with overexpressed receptor ligands into tumors appears to be a very promising therapeutic option. The inventors examined the mechanisms by which MILH induces cell death using gastrin-grafted MNP specifically administered to lysosomes of tumor cells of different cancers. The inventors demonstrate that MILH causes cell death via a non-apoptotic signaling pathway. The mechanism of cell death involves raising the temperature at the periphery of the nanoparticles that enhances the production of reactive oxygen species by the lysosomal Fenton reaction. Subsequently, MILH induces lipid peroxidation, permeabilization of the lysosomal membrane and leakage of lysosomal enzymes into the cytosol, including cathepsin-B which activates caspase-1 but not caspase-3. Thus, the invention relates to a magnetic nanoparticle grafted with a tumor targeting agent for use in a method for inducing non-apoptotic signaling of a cancer cell in a subject suffering from a cancer requiring such treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111991564-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111847522-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114939187-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113521010-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110898035-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110898035-B |
| priorityDate |
2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |